BOSTON--(BUSINESS WIRE)--Apr. 23, 2018--
Verastem, Inc. (NASDAQ: VSTM), focused on developing and commercializing
drugs to improve the survival and quality of life of cancer patients,
today announced that it will host an Analyst and Investor Day titled,
“Duvelisib: Harnessing the Power of Dual PI3K Inhibition,” on
Wednesday, May 2, 2018 from 10:30 am – 1:00 pm ET in New York City.
The agenda will include an in-depth discussion of the Company’s lead
oral oncology candidate, duvelisib, including the unmet need of
patients, where phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma
inhibitors fit into the treatment paradigm and the opportunity for
duvelisib in the growing chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL) and follicular lymphoma (FL) population and beyond.
The program will also feature key opinion leaders in the hematologic
oncology field, including:
Jennifer Brown, MD, PhD
Associate Professor of Medicine,
Harvard Medical School Director, and Director, CLL Center of the
Division of Hematologic Malignancies, Dana-Farber Cancer Institute
Ian Flinn, MD, PhD
Director, Blood Cancer Research Program at
Sarah Cannon Research Institute, and Lead Investigator of the DUO and
Steven Horwitz, MD
Medical Oncologist, Memorial Sloan
Kettering Cancer Center and NYC Health + Hospitals/Bellevue
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd
Medical Director of the Chronic Lymphocytic Leukemia (CLL) Society and
Lori Kunkel, MD
Oncology Drug Development Expert and Biotech
Advisor, Member of the Board of Directors at Tocagen Inc., Former
Chief Medical Officer, Pharmacyclics
Kindly reach out to Marianne Lambertson at firstname.lastname@example.org
for any inquiries.
A live and archived webcast of the event will be available on the
“Events and Presentations” page in the “Investors” section of the
Company’s website at www.verastem.com.
The webcast will be archived for a period of 90 days following the
conclusion of the live event.
About Verastem, Inc.
Verastem, Inc. (Nasdaq:VSTM) is a biopharmaceutical company focused on
developing and commercializing drugs to improve the survival and quality
of life of cancer patients. Verastem is currently developing duvelisib,
a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully
met its primary endpoint in a Phase 2 study in indolent non-Hodgkin
lymphoma and a Phase 3 clinical trial in patients with chronic
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Verastem has
submitted a New Drug Application (NDA) requesting the full approval of
duvelisib for the treatment of patients with relapsed or refractory
CLL/SLL, and accelerated approval for the treatment of patients with
relapsed or refractory follicular lymphoma (FL). The FDA has accepted
the NDA for filing with Priority Review and given a target action date
of October 5, 2018. In addition, Verastem is developing the focal
adhesion kinase inhibitor defactinib, which is currently being evaluated
in three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic cancer, ovarian cancer, non-small cell lung
cancer, and mesothelioma. Verastem’s product candidates seek to treat
cancer by modulating the local tumor microenvironment and enhancing
For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180423005198/en/
Source: Verastem, Inc.
Marianne M. Lambertson, 781-292-4273
President, Corporate Communications